Lymph Node Ratio and Kras Mutation in R Colon Cancer

Phase 3CompletedNCT04342676

Mansoura University433 enrolled

Overview

clinical impact of LN ratio with Kras expression in colon cancer

LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

433

Conditions

Colon Cancer Stage III

Interventions

k rasDEVICE

K ras

PanitumumabDRUG

vectibex in stage iv

Eligibility

Sex: ALLMin age: 16 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Stage III colon cancer Exclusion Criteria: * Stage I, II, IV

Locations (1)

Mansoura University Oncology Center

Al Mansurah, Dakahlia Governorate, Egypt

Outcomes

Primary Outcomes

LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).

impact on response

Time frame: 2 years

Secondary Outcomes

LNR and K ras were evaluated and ASSOCIATION with PFS and OS.

impact on survival

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.